55 / 1084
EUS - Reassessment after neoadjuvant chemotherapy (NAC)
Challenges for EUS post neoadjuvant therapy
•
Unable to differentiate fibrosis / inflammation from tumour
(resulting in over-staging)
•
Unable to detect microscopic of viable tumour
(resulting in
under-staging)
•
T staging accuracy 29%
•
Overstaged 23/45
(51%)
•
Understaged 7/45
(16%)
•
N staging accuracy 62%
•
Conclusion: EUS is an unreliable tool for staging esophageal
cancer after NAC*
*Heinzow, H. S., H. Seifert, et al. (2013). J Gastrointest Surg
17
(6): 1050-1057.